Faculty, Staff and Student Publications
Publication Date
3-1-2023
Journal
Cancer Medicine
DOI
10.1002/cam4.5426
PMID
36372937
PMCID
PMC9877941
PubMedCentral® Posted Date
November 2022
PubMedCentral® Full Text Version
Post-print
Abstract
Neutrophil-to-lymphocyte ratio (NLR) has been studied as a prognostic factor for mortality in COVID-19 patients. Our study aimed to evaluate the association between NLR at COVID-19 diagnosis and survival during the following 90 days in hospitalized patients with solid cancer. Between May 2020 and June 2021, 120 patients were included in a retrospective cohort study. Univariable analysis showed patients with an NLR > 8.3 were associated with an increased risk of death (HR: 4.34; 95% CI: 1.74-10.84) compared to patients with NLR < 3.82 and with NLR ≥3.82 and ≤8.30 (HR: 2.89; 95% CI: 1.32-6.36). Furthermore, on multivariable analysis, NLR > 8.30 independently correlated with increased mortality. In patients with solid malignancies with COVID-19, an NLR > 8.3 is associated with an increased risk of death.
Keywords
Humans, Neutrophils, COVID-19, Lymphocyte Count, Retrospective Studies, COVID-19 Testing, Prognosis, Lymphocytes, Neoplasms
Published Open-Access
yes
Recommended Citation
Díaz-Couselo, Fernando A; Flagel, Santiago; Nicolini, Carla; et al., "Impact of High Neutrophil-to-Lymphocyte Ratio on Survival in Hospitalized Cancer Patients With COVID-19" (2023). Faculty, Staff and Student Publications. 1615.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/1615
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Clinical Epidemiology Commons, Community Health and Preventive Medicine Commons, COVID-19 Commons, Medical Sciences Commons, Oncology Commons